(Press-News.org)
SCOTTSDALE, Ariz. — Jan. 27, 2026 — Cancer research laboratory tests can now be done using micro-physiological systems mimicking the human physiology, allowing greater predictive accuracy for human patientresponses, thanks to an international scientific team led by HonorHealth Research Institute and the University of Arizona.
Their findings from a simulated radiation treatment for lung cancer are summarized in a paper published in the scientific journal iScience entitled: A human 3D culture-organ-on-chip platform for investigating the tumor microenvironment response to ionizing radiation (10.1016/j.isci.2025.114236).
“We can be more precise and accurate than we’ve been. And eventually, better understand some of the mechanisms that drive the complex human tumor microenvironment (TME) interactions and how to guide treatment,” said Frederic Zenhausern, Ph.D., MBA, senior author of the paper, a senior scientist at HonorHealth Research Institute, and professor and director of the Center for Applied NanoBioscience and Medicine at the University of Arizona College of Medicine – Phoenix.
“Studying complex human responses … requires advanced in vitro (laboratory) systems,” according to the paper. “Here, we present the Apparatus to Simulate Tumor Environment
and Reproduce Organs in an Interactive and Dynamic System (ASTEROIDS), which integrates three-dimensional cell culture with organ-on-chip technology. These results demonstrate that ASTEROIDS faithfully reproduces TME-level organization and responses, establishing its feasibility as a pre-clinical human model.”
While the simulation described in the paper focused on lung cancer, the technology can be applied to any solid tumor, Dr. Zenhausern said: “This platform will play a significant role moving forward.”
This technology aligns with new FDA policies, under the FDA Modernization Act 2.0, to reduce animal testing in the development of advanced molecular therapies and other drugs with more human-relevant methods using multiple approaches, including AI-based computational models, organ-on-chip, and organoid testing in laboratory settings (so-called New Approach Methodologies or NAMs).
ASTEROIDS technology is also under joint product development with Japan’s Mitsubishi Gas Chemical Company Inc. for future commercialization to improve the efficacy of translating the results of pre-clinical models to human clinical outcomes.
Characterization of ASTEROIDS
The 3D nature of ASTEROIDS combines cell culture and organ-on-chip technology, supports long-term cell viability and tissue barrier integrity, enables cell-to-cell communication and tumor-immune crosstalk, and provides a human-relevant platform for therapy testing.
“This TME provides a unique biological landscape, including multiple properties through its three-dimensional cellular morphology, the biochemical signaling governing the interaction of its multi-cellular components, and the mechanical forces occurring during tumor initiation, progression, invasion, and dissemination,” the paper said.
The three-dimensional design enables the ASTEROIDS platform to act in a spatial organization that closely mimics the actions and reactions of a living organism, according to the paper: “We showed that the ASTEROIDS allowed the mechanical and biochemical interactions between the different cells, thus recapitulating key tissue hallmarks commonlydescribed with in vivo (living cell) observations.”
National and international contributors
Led by Dr. Zenhausern and U of A Assistant Professor Dr. Jerome Lacombe, this multi-institutional collaboration integrates expertise from radiobiologists, oncologists and engineers to deliver an interdisciplinary advance in medicine.
Support for this study came from: National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), St. Joseph’s Foundation, Helios Education Foundation, Valley Research Partnership Program, and the HonorHealth Research Institute Rare Cancer Initiative supported by Desert Mountain CARE.
Additional support was provided by Mitsubishi Gas Chemical Company.
Also contributing to this study’s research were researchers at University of Geneva, Georgetown University, St. Joseph’s Hospital and Medical Center, and Mitsubishi Gas Chemical Company.
For more about HonorHealth Research Institute clinical trials: call 833-354-6667; or email clinicaltrials@HonorHealth.com.
# # #
About the HonorHealth Research Institute
HonorHealth Research Institute is an international destination that is at the forefront of providing patients with a better quality of life through its clinical trials and innovative treatment options. Headquartered in Scottsdale, Arizona, the institute’s team of physicians and researchers collaborate with experts from across the nation to offer life-changing therapies, drugs and devices. At HonorHealth Research Institute, patients have access to tomorrow’s health innovations, today. Learn more at: HonorHealth.com/research.
END
OKLAHOMA CITY – A newly approved National Cancer Institute-funded clinical trial aims to improve survival for head and neck cancer patients whose disease returns after radiation therapy – a setback that affects up to 40% of patients and is often associated with poor outcomes.
For these patients, surgery is currently the standard treatment, typically targeting tumors in the mouth, throat or lymph nodes of the neck. This Phase II trial will examine whether giving chemotherapy, or chemotherapy combined with immunotherapy, before surgery can improve survival compared with surgery alone.
“Even when a patient is a good surgical candidate, the operation is often aggressive ...
New research shows that after the body’s defenses kill the virus behind COVID-19, leftover digested chunks of SARS-CoV-2 spike protein can target specific immune cells based on their shape. The revelations could explain why certain populations of cells that detect and fight infection are depleted in patients with severe COVID-19, and shed light on the omicron variant’s milder symptoms.
The study, published in the Proceedings of the National Academy of Sciences, may launch a line of inquiry that informs new strategies for quelling the most serious symptoms of COVID-19. Led by a UCLA team, the scientific collaboration ...
Virginia Tech researchers discovered an indication hidden in the brain that may help doctors identify children suffering from a rare genetic disease earlier. Their findings were published recently in EMBO Molecular Medicine.
Leigh syndrome is a severe neurological disorder that affects the mitochondria, which are energy factories found in almost all the cells of the body. This disease typically appears in infancy and can progress rapidly, leading to limited treatment options and poor survival rates.
Prenatal tests for mitochondrial disorders like Leigh syndrome ...
Microbes across Earth’s coldest regions are becoming more active as glaciers, permafrost and sea ice thaw, accelerating carbon release and potentially amplifying climate change, according to a new international review from McGill University.
Drawing on data from polar and alpine environments worldwide, the researchers found that warming is driving faster microbial metabolism, increasing the breakdown of organic matter and the release of greenhouse gases such as carbon dioxide and methane into the ...
NEW YORK, NY– Today, the Vertebrate Genome Laboratory, led by Erich Jarvis and Co-Directors Giulio Formenti and Jennifer Balacco, at The Rockefeller University, has received funding as part of Google.org's $20 million AI for Science Fund to support organizations focused on cutting-edge AI for science research. The funding has been awarded to twelve academic and nonprofit organizations around the world that are using AI to address increasingly complex problems at the intersections of various disciplines of science. The proportion ...
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the University of British Columbia are extending those possibilities to the skin for the first time.
The UBC team, together with researchers from the Berlin Institute of Health at Charité in Germany, has developed the first gene therapy capable of correcting faulty genes when applied directly to human skin. Outlined today in a paper published in Cell Stem Cell, the breakthrough could lead ...
PORTLAND, Ore. – Scientists at Oregon State University have developed a new nanomaterial that triggers a pair of chemical reactions inside cancer cells, killing the cells via oxidative stress while leaving healthy tissues alone.
The study led by Oleh and Olena Taratula and Chao Wang of the OSU College of Pharmacy was published this week in Advanced Functional Materials.
The findings advance the field of chemodynamic therapy or CDT, an emerging treatment approach based on the distinctive biochemical environment found in ...
A solar energy generation technology once considered limited in its potential is poised for significant growth in the United States.
That’s the conclusion of a team of scientists who analyzed the outlook for cadmium telluride photovoltaics in research published in the peer-reviewed journal Joule.
University of Toledo physicists including Dr. Michael Heben, a Distinguished University Professor and McMaster Chair and Director of the Wright Center for Photovoltaics Innovation and Commercialization, collaborated with partners at the U.S. Department of Energy’s National Laboratory ...
WEST LAFAYETTE, Ind. — A Purdue University team led by Kyle Cottrell has discovered a new therapeutic target for triple-negative breast cancer.
“Triple-negative breast cancer is a particularly deadly form of breast cancer that currently lacks targeted therapies,” said Cottrell, an assistant professor of biochemistry. Cottrell, biochemistry graduate student Addison Young and their co-authors describe the discovery in the journal RNA.
The laboratory research spotlights double-stranded ribonucleic acid (dsRNA)-binding proteins. ...
PHILADELPPHIA—Patients were 28 percent more likely to get a flu shot when they got a text message reminder and their primary care provider already had an order for the shot waiting, new research from the Perelman School of Medicine showed. The study was published in JAMA Internal Medicine.
“This is important given the rise in vaccine hesitancy, which has resulted in a downward trend in flu vaccination that coincided with a high rate of hospitalization this flu season,” said the study’s lead author, Shivan Mehta, MD, MBA, MSHP, associate chief innovation officer at Penn Medicine. “Many nudge interventions directed to patients only on vaccinations have shown ...
